ArticleFrontiers in cardiovascular medicine2023
The prevalence of cardiometabolic multimorbidity and its associations with health outcomes among women in China.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Associations of three metabolic biomarkers with the risk of cardiometabolic multimorbidity: a national prospective study.Lipids in health and disease · 2026Article
- Article
- Cardiometabolic multimorbidity prevalence and its socio-demographic determinants among Iranian adults: insights from the nationwide STEPS 2021.Scientific reports · 2026Article
- Joint association of atherogenic index of plasma (AIP) and body roundness index (BRI) with cardiometabolic multimorbidity in adults in Guangzhou, China.Cardiovascular diabetology · 2026Article
- Changes in the estimated glucose disposal rate and cardiometabolic multimorbidity in middle-aged and older adults.Cardiovascular diabetology · 2026Article
- Article
- Comparative predictive values of anthropometric indices for cardiometabolic multimorbidity in middle-aged and older adults: a prospective study from the CHARLS study.BMC public health · 2025Article
- Risk prediction of multiple cardiometabolic diseases in middle-aged and older adults using lipid metabolism biomarkers and derived composite measures based on machine learning: a prospective cohort study of CHARLS.Lipids in health and disease · 2025Article
- Cardiometabolic multimorbidity (CMM) among older adults in India.BMC cardiovascular disorders · 2025Article
- The correlation between different metabolic scores and the risk of cardiometabolic comorbidities in hypertensive patients.Scientific reports · 2025Article
- Illness Perception, Health Literacy, and Medication Adherence in Hypertensive Patients and Their Spouses: An Actor-Partner Interdependence Mediation Model Approach.Patient preference and adherence · 2025Article
- Cardiometabolic multimorbidity, peripheral biomarkers, and dementia in rural older adults: The MIND-China study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Impact of vitamins A, D, and homocysteine on cardiometabolic multimorbidity in Northwest China.Nutrition & metabolism · 2024Article
- Association between Dietary Patterns and Cardiometabolic Multimorbidity among Chinese Rural Older Adults.Nutrients · 2024Article
- Transition between cardiometabolic conditions and body weight among women: which paths increase the risk of diabetes and cardiovascular diseases?Journal of human hypertension · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In China, a limited number of studies focus on women and examine the effect of cardiometabolic multimorbidity (defined as the presence of two or more cardiometabolic diseases) on health outcomes. This research aims to investigate the epidemiology of cardiometabolic multimorbidity and the association of cardiometabolic multimorbidity with long-term mortality. Methods: This study used data from the China Health and Retirement Longitudinal Study between 2011 and 2018, which includes 4,832 women aged 45 years and older in China. Poisson-distributed Generalized Linear Models (GLM) were applied to examine the association of cardiometabolic multimorbidity with all-cause mortality. Results: Overall, the prevalence of cardiometabolic multimorbidity was 33.1% among the total sample of 4,832 Chinese women, and increased with age, ranging from 28.5% (22.1%) for those aged 45-54 years to 65.3% (38.2%) for those aged ≥75 years in urban (rural) areas. Compared with the group of none and single disease, cardiometabolic multimorbidity was positively associated with all-cause death (RR = 1.509, 95% CI = 1.130, 2.017), after adjusting socio-demographic and lifestyle behavioral covariates. Stratified analyses revealed that the association between cardiometabolic multimorbidity and all-cause death was only statistically significant (RR = 1.473, 95% CI = 1.040, 2.087) in rural residents, but not significant in urban residents. Conclusion: Cardiometabolic multimorbidity is common among women in China and has been associated with excess mortality. Targeted strategies and people-centered integrated primary care models must be considered to more effectively manage the cardiometabolic multimorbidity shift from focusing on single-disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.